Premaitha Health PLC IONA test validation on Thermo Fisher's Ion S5 (2841G)
26 May 2017 - 4:00PM
UK Regulatory
TIDMNIPT
RNS Number : 2841G
Premaitha Health PLC
26 May 2017
Premaitha Health plc
Premaitha completes IONA test validation on Thermo Fisher's Ion
S5 instrument
Manchester, UK - 26 May 2017: Premaitha Health plc (AIM: NIPT,
"Premaitha" or the "Company"), a leading international molecular
diagnostics group focused on prenatal testing, announces that the
IONA(R) test, the Company's CE-IVD non-invasive prenatal test
("NIPT"), has been validated for use on Thermo Fisher Scientific's
Ion S5 range of instruments.
The validation of the IONA(R) test on the Ion S5 platform,
performed in partnership with Thermo Fisher Scientific, will
broaden Premaitha's potential laboratory customer base. The Ion S5
instrument is now being widely adopted by laboratories carrying out
next generation DNA sequencing around the world. The IONA(R) test
is therefore now a possible NIPT solution for this growing network
of laboratories. Additionally, as the Ion S5 can be used for wider
applications, including oncology, the platform allows Premaitha to
work with lower volume laboratories that are keen to offer NIPT as
part of a wider choice of genetic tests for their patient
populations.
The IONA(R) test is already validated on Thermo Fisher
Scientific's Ion Proton and Ion Chef sequencing instruments (part
of the same Ion Torrent platform).
Dr Stephen Little, CEO, commented: "Validation on the Ion S5 is
another important technological milestone which achieves a simpler
IONA(R) test workflow, enabling less 'hands-on' time, and provides
access to an even greater pool of international laboratory
customers that are installing the new platform or who are not
solely focused on NIPT. We already have several S5 laboratories
ready to roll out the IONA(R) test, and are in discussions with
more."
For more information, please contact:
Premaitha Health plc Tel: +44 (0)
161 667 6865
Dr Stephen Little, Chief Executive
Office
Barry Hextall, Chief Financial
Officer
Joanne Cross, Head of Marketing
investors@premaitha.com
Cairn Financial Advisers LLP (Nomad) Tel: +44 (0)
20 7213 0880
Liam Murray / James Caithie
finnCap (Broker) Tel: +44 (0)
20 7220 0500
Adrian Hargrave / Scott Mathieson
(Corporate Finance)
Tony Quirke (Corporate Broking)
Vigo Communications Tel: +44 (0)
20 7830 9700
Ben Simons / Fiona Henson / Antonia
Pollock
premaitha@vigocomms.com
About Premaitha
Premaitha is an international molecular diagnostics group which
uses the latest advances in DNA analysis technology to develop
safer, faster and regulatory approved genetic screening tests. The
Group's primary focus is on non-invasive prenatal tests (NIPT) for
pregnant women - an emerging, multi-billion dollar global
market.
Premaitha's IONA(R) test was launched in 2015 as the first
CE-IVD NIPT test in Europe. It enables laboratories and healthcare
practitioners to offer a complete CE-marked NIPT system in-house.
The IONA(R) test is performed on a maternal blood sample - which
contains traces of fetal DNA - and estimates the risk of a fetus
being affected with Down's syndrome or other genetic
conditions.
Unlike existing prenatal screening methods, due to its high
level of accuracy, the IONA(R) test can significantly reduce the
number of women subjected to unnecessary invasive follow up
diagnostic procedures, such as amniocentesis, which are costly,
resource intensive and carry a risk of miscarriage.
In March 2017, Premaitha acquired Yourgene Bioscience, a
specialist next generation sequencing and bioinformatics company
based in Taiwan, with its own NIPT screening test that operates on
the same Thermo Fisher next-generation sequencing platform as
Premaitha's IONA(R) test. Yourgene brings significant benefits to
the Group through expanded market access in Asia - the world's
fastest growing NIPT market - as well as opportunities for
cross-selling and the ability to jointly develop expanded test
content both within NIPT and beyond.
Premaitha is headquartered in Manchester, England, with Yourgene
offices in Taipei and Singapore. Its shares trade on the AIM market
of the London Stock Exchange (AIM: NIPT). For further information,
please visit www.premaitha.com. Follow us on twitter
@PremaithaHealth.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCBUGDULXDBGRU
(END) Dow Jones Newswires
May 26, 2017 02:00 ET (06:00 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From May 2023 to May 2024